On the Path to Net Zero: TIWAG Subsidiary TINEXT to Supply INNIO’s Primary Operations in Jenbach with Green Hydrogen
22.9.2022 15:00:00 EEST | Business Wire | Press release
INNIO and TIWAG today announce that TINEXT, a TIWAG (Tiroler Wasserkraft AG) subsidiary, will supply INNIO’s primary operations in Jenbach with green hydrogen (H2) by 2025. At the same time, excess power and heat will be fed into the local power grid and district heating network. Once sufficient quantities of green hydrogen are available, additional areas of application are planned, such as supplying an INNIO plant gas station or refueling local logistics companies’ vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005259/en/
Vice president and site manager of INNIO's Jenbacher site Martin Mühlbacher, TIWAG managing director Dipl.-Ing Thomas Gasser, and INNIO president and CEO Dr. Olaf Berlien. (Photo: Business Wire)
As part of the joint project, INNIO will install an electrolysis unit on the premises of TIWAG’s Achensee power plant that will convert green electricity into green hydrogen. In turn, TINEXT will construct the compression and storage terminals. The hydrogen, a key component in the energy transition, will be transported via pipeline from TINEXT to INNIO’s main operations in Jenbach, where it will primarily be used for hydrogen engine test runs.
“The hydrogen agreement with TIWAG and TINEXT is another milestone on our path to net zero at our site in Jenbach,” said Olaf Berlien, president and CEO of INNIO. “We have committed to reducing emissions from our production sites around the world by up to 50% by 2030. The products of the future are being developed here in our INNIO360 Energy Lab, where we demonstrate how the energy transition works.”
“Using green hydrogen to generate power is an important step on INNIO’s journey to significantly reduce the carbon footprint of the site in Jenbach,” said Martin Mühlbacher, vice president and site manager in Jenbach. “Along with the use of a photovoltaic system, hydropower plant, battery storage, storage water heater (power-to-heat), and electromobility, this will make an important contribution to implementing our broad-ranging sustainability strategy.”
“This pioneering hydrogen project is a central element of Tyrol’s energy strategy of phasing out the use of fossil fuels. With this agreement, INNIO and TIWAG are showing how the transition to an energy-autonomous and climate-neutral energy supply for industrial companies can be realized,” commented TIWAG managing director Dipl.-Ing Thomas Gasser. “TIWAG has been using hydropower to generate green electricity in Jenbach for almost 100 years. As of this summer, this is supported by a large photovoltaic system. It is all the more gratifying that our subsidiary TINEXT is now suppling green hydrogen for our customer and partner INNIO at this location, which has a long tradition in power generation.”
The availability of green hydrogen is an important prerequisite for the sustainable, economic, and timely implementation of INNIO’s hydrogen strategy. The company began offering all new Jenbacher engines with a “Ready for H2” option this year.
About TIWAG
TIWAG, the state energy utility owned by the State of Tyrol, is tasked with providing a secure, sustainable, and integrated energy supply for Tyrol. The TIWAG Group supports the European and national energy goals and is a driving force behind the ecological transition in Tyrol’s power, gas, and heat supply. TINEXT – TIWAG Next Energy Solutions GmbH, the 100% subsidiary established in 2021, supports the energy transition in the fields of hydrogen, photovoltaics, renewable heat, and electromobility.
About INNIO
INNIO is a leading energy solution and service provider that empowers industries and communities to make sustainable energy work today. With our product brands Jenbacher and Waukesha and our digital platform myPlant, INNIO offers innovative solutions for the power generation and compression segments that help industries and communities generate and manage energy sustainably while navigating the fast-changing landscape of traditional and green energy sources. We are individual in scope, but global in scale. With our flexible, scalable, and resilient energy solutions and services, we are enabling our customers to manage the energy transition along the energy value chain wherever they are in their transition journey.
INNIO is headquartered in Jenbach (Austria), with other primary operations in Waukesha (Wisconsin, U.S.) and Welland (Ontario, Canada). A team of more than 3,500 experts provides life-cycle support to the more than 54,000 delivered engines globally through a service network in more than 80 countries.
INNIO’s ESG Risk Rating places it number one of more than 500 worldwide companies in the machinery industry assessed by Sustainalytics.
For more information, visit INNIO’s website at www.innio.com. Follow INNIO on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005259/en/
Contact information
Susanne Reichelt
INNIO, Media Relations
+43 664 80833 2382
susanne.reichelt@innio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
